The company works with customers to develop specialized, customized packaging solutions for pharmaceutical products, with a focus on compliance and delivering products as intended and efficiently.
Theratechnologies completes its acquisition by Future Pak through Future Pak affiliate CB Biotechnology, LLC, under a plan of arrangement. The transaction provides shareholders US$3.01 per share in cash, plus a contingent value right that could deliver up to an additional US$1.19 per share.
Theratechnologies receives final court approval for its proposed acquisition by Future Pak. Under the plan of arrangement, Future Pak, through its affiliate CB Biotechnology, LLC, would acquire all issued and outstanding common shares of Theratechnologies.
Theratechnologies shareholders approve a proposed plan of arrangement for Future Pak to acquire the company. Under the plan, Future Pak’s affiliate CB Biotechnology, LLC, would acquire all issued and outstanding Theratechnologies common shares.
Theratechnologies says independent proxy advisory firms ISS and Glass Lewis recommend that shareholders vote for its proposed plan of arrangement with Future Pak. The company says its board unanimously recommends the same.
